Growth Metrics

Merck (MRK) Cash & Current Investments (2016 - 2026)

Merck has reported Cash & Current Investments over the past 18 years, most recently at $5.7 billion for Q1 2026.

  • Quarterly Cash & Current Investments fell 38.21% to $5.7 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $5.7 billion through Mar 2026, down 38.21% year-over-year, with the annual reading at $14.6 billion for FY2025, 6.4% up from the prior year.
  • Cash & Current Investments was $5.7 billion for Q1 2026 at Merck, down from $14.6 billion in the prior quarter.
  • Over five years, Cash & Current Investments peaked at $18.2 billion in Q3 2025 and troughed at $5.6 billion in Q1 2024.
  • The 5-year median for Cash & Current Investments is $10.1 billion (2022), against an average of $10.5 billion.
  • Year-over-year, Cash & Current Investments plummeted 46.23% in 2023 and then skyrocketed 92.99% in 2024.
  • A 5-year view of Cash & Current Investments shows it stood at $13.2 billion in 2022, then plummeted by 46.23% to $7.1 billion in 2023, then soared by 92.99% to $13.7 billion in 2024, then rose by 6.4% to $14.6 billion in 2025, then tumbled by 60.85% to $5.7 billion in 2026.
  • Per Business Quant, the three most recent readings for MRK's Cash & Current Investments are $5.7 billion (Q1 2026), $14.6 billion (Q4 2025), and $18.2 billion (Q3 2025).